HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger

Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb proof-of-concept trials.

By Pharmaceutical Technology · Jun 30, 2026 · via Pharmaceutical Technology
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
BeOne's Brukinsa hits goal in mantle cell lymphoma confirmatory trial
A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a "n…
Jun 30, 2026
The WeekFierceBiotech ↗
Praxis faces FDA decision delay as analysts point finger at agency layoffs
The FDA has delayed a decision on the approval of Praxis Precision Medicine's rare epilepsy prospect by three …
Jun 30, 2026
FDA Updates List of Off-Patent Drugs Without Approved Generics
The WeekBriefing
FDA Updates List of Off-Patent Drugs Without Approved Generics
The FDA’s June 2026 update again highlights brand drugs still lacking generic challengers, aiming to spur ANDA…
Jun 30, 2026